Keywords: European Union, EGA, Anti-falsification technologies, Counterfeit drugs, Cost implications

Access to low-price generics threatened by technologies due to be used in EU

Article | 30 April 2012

Producers of generic medicines are raising concerns on the huge cost implications of possible new anti-falsification technologies that will be ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in